Eloxx Pharmaceuticals — Valuation, Funding & Investors

Recent changes

Sep 11, 2026Sep 11, 2026IPO an undisclosed amount SEC EDGAR
Sep 11, 2026Sep 11, 2026Eloxx Pharmaceuticals Files To Uplist From OTC To Nasdaq Pulse story

Funding History

1 event · sources dated per row

Date	Event	Amount	Valuation	Investors	Source
Sep 11, 2026	ipo	—	—		SEC EDGAR

Latest Pulse

Sep 11, 2026Eloxx Pharmaceuticals Files To Uplist From OTC To NasdaqEloxx Pharmaceuticals filed an S-1 to uplist from the OTC Pink market to Nasdaq, offering 2.73 million shares plus pre-funded warrants at an assumed $10-12 per share to fund its rare-kidney-disease drug candidate.→

Coverage Timeline

newest first

Sep 11, 2026IPOEloxx Pharmaceuticals Files To Uplist From OTC To Nasdaq→

All Coverage

IPO· Sep 11, 2026

Eloxx Pharmaceuticals Files To Uplist From OTC To Nasdaq

IPO

Eloxx Pharmaceuticals Files To Uplist From OTC To Nasdaq

Eloxx Pharmaceuticals filed an S-1 to uplist from the OTC Pink market to Nasdaq, offering 2.73 million shares plus pre-funded warrants at an assumed $10-12 per share to fund its rare-kidney-disease drug candidate.

Sep 11, 2026DEEP DIVE

Related Companies

Same sector

Attovia Therapeutics Apnimed Braveheart Bio Latigo Biotherapeutics Scribe Therapeutics

Sources & methodologyshow

Where these figures come from

SEC EDGARprimary source1 fact

Figures are labelled Reported (a source states it), Estimated, Derived (computed from other facts) or Rumored (in talks / unconfirmed). Rumors never replace a confirmed figure. Each figure keeps its own as-of date; history is preserved rather than overwritten.

How we verify data · Suggest a correction